MolecuLight^® improves success with

This study used MolecuLight fluorescence imaging to objectively identify the most effective cleansing methods and solutions for wound care. The findings provide valuable insights for developing evidence-based wound cleansing protocols.

This pilot study set the stage for the larger, 350-patient FLAAG clinical validation trial.

MolecuLight imaging provided real-time guidance for debridement and antibiotic selection in chronic lower extremity wounds. Removal of bacterial fluorescence signals was associated with reduced wound areas.

MolecuLight imaging showed zinc oxide bandages significantly reduced perilesional bacterial load in VLUs more than short stretch bandages, without differing in pain relief.

MolecuLight imaging demonstrated that zinc oxide bandages significantly reduced bacterial load in VLUs compared to traditional multicomponent dressings.

MolecuLight imaging revealed the inadequacy of standard debridement highlighting the need for objective visualization of bacterial burden.

MolecuLight-guided curettage or biopsy sampling positively predicted bacterial presence in wounds at potentially harmful levels, entirely eliminating the risk of false negative sampling.

Wound measurement accuracy was validated at >95% using the MolecuLight i:X device,​ and fluorescence imaging before and after standard debridement revealed persistence​ of bacterial fluorescence in 100% of DFUs.

Fluorescence imaging demonstrated superior sensitivity (84%) and accuracy (63%) compared to clinical signs of biofilm (sensitivity 44% and accuracy 43%) and biofilm blotting (sensitivity 24% and accuracy 40%).

MolecuLight-targeted sampling demonstrated superior accuracy versus Levine swabbing in detecting high bacterial loads, also identifying a greater diversity of bacterial species within wounds.

This study reveals the limitations of relying on clinical signs and symptoms for detecting harmful bacteria in DFUs. The concept of “chronic inhibitory bacterial load” (CIBL) is introduced, with MolecuLight imaging vastly improving its detection for better wound care.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

RCT evidence that MolecuLight imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%) and the presence/absence of bacterial fluorescence reliably predicted the degree of wound closure.

A retrospective review across 55 long-term care facilities showing that MolecuLight significantly improved pressure injury outcomes compared to standard care alone. Patients treated with MolecuLight experienced a 71% higher healing rate, healed 28% faster, were 1.4 to 1.8 times more likely to heal, and experienced 75% fewer complications.

In this validation study, clinicians found that MolecuLight was easy to use and greatly reduced the time taken waiting for microbiology results.

All wounds positive for UPPER/LOWER were also positive with MolecuLight. In many cases the fluorescence information added a third check to the UPPER/LOWER score, turning a negative diagnosis of infection into a positive one.

MolecuLight imaging demonstrated a sensitivity of 100%, specificity of 78%, PPV of 95% and NPV of 100% for identification of pathologic bacteria in wounds.

A multi-site trial validating MolecuLight fluorescence imaging demonstrated significant improvement in detection of bacterial burden compared to standard assessment. 69% of treatment plans were informed by fluorescence imaging.

MolecuLight imaging prevented the need for intravenous antibiotics and hospitalization in 100% of wound-related cellulitis cases by aiding in early diagnosis and bacterial source control.

Fluorescence imaging predicted wound area reduction based on bacterial presence, with persistent bacterial loads correlating to worse outcomes. MolecuLight digital wound measurements were significantly more accurate than manual measurements (23% overestimation with ruler).

Fluorescence-targeted mechanical debridement using MolecuLight safely reduced bacterial loads with minimal patient discomfort, yielding results comparable to sharp debridement.

MolecuLight enhanced mechanical wound debridement by visualizing bacterial presence, enabling targeted removal and significantly reducing bacterial load.

A real-world multisite study of 1000 wounds showed that fluorescence imaging frequently revealed harmful bacterial presence missed during routine inspection. Providers changed their course of clinical action over half the time, most commonly extending hygiene/debridement or targeting debridement to MolecuLight positive areas.

MolecuLight imaging visualized in real-time pseudomonal infection progression and treatment efficacy in a shell-less hen’s egg model.

Fluorescence imaging visualized porphyrin production from 28 bacterial species (Gram +, Gram -, aerobic, anaerobic), including those in biofilm.

The first study to demonstrate detection of bacterial biofilm in mouse wound models using bacterial fluorescence imaging.

MolecuLight imaging provided a novel and effective method that supports standard of care in managing organ/space surgical site infections after kidney transplantation.

Standard assessment missed high bacterial loads in most surgical wounds referred to specialists. MolecuLight imaging significantly improved detection, demonstrating its potential to optimize post-surgical care.

Perineal tear wounds with bacterial fluorescence exhibited delayed healing compared to noncolonized wounds, with fluorescence being a statistically significant predictor of this delay.

This study demonstrated the high diagnostic accuracy (83% sensitivity, 90% specificity) of bacterial fluorescence imaging in detecting clinically significant bacterial burden in perineal wounds, enabling informed treatment decisions at the point-of-care.

Fluorescence imaging provided actionable insights on bacterial burden, enabling informed and localized treatment decisions that reduced antibiotic overuse.

MolecuLight imaging enhanced communication and collaboration between wound care teams, leading to improved assessment accuracy and standardized treatment interventions.

Fluorescence imaging objectively guided clinicians to bacterial hotspots, yielding higher bacterial loads and more reliable microbial profiles.

Fluorescence imaging provided objective and actionable information at the bedside, which led to a decrease in the use of antibiotics.

MolecuLight digital wound measurements were significantly more accurate than manual measurements (23% overestimation with ruler).

In this statistically powered validation study of 17 3D wound models and 34 clinical wounds, AutoDepth measurements were highly accurate with excellent reproducibility in both benchtop and clinical testing.

Compared to standard examination, MolecuLight fluorescence imaging offered a superior method for detecting bacterial burden in burn wounds, allowing for targeted swabbing of bacterial-laden regions within large wounds.

MolecuLight imaging reliably predicted burn wound infections following split-thickness​ skin grafting, with positive and negative predictive values of 82% and 90%.

First study to show that fluorescence imaging can visualize clinically significant bacterial burden in pediatric burn wounds and is easily incorporated into routine pediatric burn wound assessment.

MolecuLight significantly improved the accuracy of identifying wound infections in pediatric burn patients compared to visual assessment alone, in turn better informing wound management at the point-of-care.

This review summarizes evidence demonstrating the benefits of fluorescence imaging for burn wound assessment, with a focus on improved bacterial detection.

This tutorial equips clinicians with the knowledge to identify MolecuLight fluorescence signals in wounds, using clinical examples to aid in image interpretation. It focuses on image artifacts, potential confounders, and strategies for overcoming challenges in wound imaging.

MolecuLight imaging through NPWT dressings provided objective bacterial monitoring to better inform dressing change frequency and optimize resource utilization.

Looking for practical guidance on when to use MolecuLight®?

32 wound care experts joined forces to establish best practices on bacterial fluorescence imaging. Recommendations cover imaging workflow, patient selection criteria, and when and how often to use this technology.

MolecuLight® profoundly impacts the way clinicians approach wound treatment, revealing harmful bacteria and biofilm missed during routine inspection.

Providers changed their course of clinical action over half the time, most commonly extending hygiene/debridement or targeting debridement and sampling to MolecuLight® positive areas.

MolecuLight^® supports wound care equity by improving bacterial detection for all patients with any skin color.

This 350-patient clinical study validates the diagnostic accuracy of MolecuLight^® on all skin tones and reveals the inherent bias of standard assessment that underserves patients of color.

Fluorescence imaging enabled real-time monitoring of bacterial burden, guiding adjustments to NPWT and biofilm-disrupting agent treatments in recalcitrant pressure ulcer care.

A retrospective review across 55 long-term care facilities showing that MolecuLight significantly improved pressure injury outcomes compared to standard care alone. Patients treated with MolecuLight experienced a 71% higher healing rate, healed 28% faster, were 1.4 to 1.8 times more likely to heal, and experienced 75% fewer complications.

32 wound care experts collaborated in a Delphi consensus to develop guidance for bacterial fluorescence imaging. Recommendations cover imaging workflow, patient selection criteria, and when and how often to use this technology.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

RCT evidence that MolecuLight imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%) and the presence/absence of bacterial fluorescence reliably predicted the degree of wound closure.

MolecuLight precisely identified bacteria in pelvic pressure injuries (PIs), enhancing the understanding of PI infections, guiding treatment strategies like debridement and dressing adjustments, and enabling real-time monitoring of treatment efficacy.

The presence or absence of red or cyan on bacterial fluorescence images accurately predicted the success or failure of DFU healing after acellular matrix product placement.

This study reveals the limitations of relying on clinical signs and symptoms for detecting harmful bacteria in DFUs. The concept of “chronic inhibitory bacterial load” (CIBL) is introduced, with MolecuLight imaging vastly improving its detection for better wound care.

Wound measurement accuracy was validated at >95% using the MolecuLight i:X device, and fluorescence imaging before and after standard debridement revealed persistence of bacterial fluorescence in 100% of DFUs.

Fluorescence imaging demonstrated superior sensitivity (84%) and accuracy (63%) compared to clinical signs of biofilm (sensitivity 44% and accuracy 43%) and biofilm blotting (sensitivity 24% and accuracy 40%).

MolecuLight-targeted sampling demonstrated superior accuracy versus Levine swabbing in detecting high bacterial loads, also identifying a greater diversity of bacterial species within wounds.

MolecuLight-guided curettage or biopsy sampling positively predicted bacterial presence in wounds at potentially harmful levels, entirely eliminating the risk of false negative sampling.

MolecuLight® shows remarkable accuracy in assessing recipient sites and predicting skin graft take/loss outcomes among burn patients.

CMS requires documentation that wounds are free of infection before skin substitute/graft application. MolecuLight® is the only tool that provides graphical evidence of adequate wound bed preparation.